Business

BioNTech 4Q Rev EUR5.5B >BNTX

By Cecilia Butini

German pharmaceutical company BioNTech SE reported rising fourth-quarter profits and sales, fueled by the Covid-19 vaccine it makes with Pfizer Inc., and announced it will launch a share buyback program of up to $1.5 billion over the next two years US dollars to start.

The company reported net income of 3.17 billion euros ($3.51 billion) in the last quarter of the year, compared to 3.66 million euros a year earlier. The operating result increased from 244 million euros in the fourth quarter of 2020 to 4.70 billion euros, it said. Revenue also jumped in the quarter, rising from €345 million to €5.53 billion.

New Covid-19 vaccine orders for 2022 rose to 2.4 billion doses, the company said. It expects earnings from the shot to be between 13 and 17 billion euros this year.

BioNTech’s financial success in 2021 enabled the company to increase its R&D investment by approximately 50% year-on-year in 2022, and it is now expected to spend approximately €1.4 billion to €1.5 billion on R&D Development to spend, with a focus on oncology and infectious diseases alongside Covid-19.

BioNTech has shipped about 2.6 billion doses of its Comirnaty coronavirus vaccine in 2021, it said.

It will propose a special dividend of EUR 2 per share to the Annual General Meeting.

Write to Cecilia Butini at cecilia.butini@wsj.com

https://www.marketwatch.com/story/biontech-4q-rev-eur5-5b-bntx-271648636745?rss=1&siteid=rss BioNTech 4Q Rev EUR5.5B >BNTX

Brian Lowry

InternetCloning is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – admin@internetcloning.com. The content will be deleted within 24 hours.

Related Articles

Back to top button